Use of biologics by patients with immune-related inflammatory disease and SARS-CoV-2 infection does not appear to be associated with worse COVID-19 outcomes. In Correspondence to the editor of the NEJM, a prospective cases series comprised 86 patients with underlying rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease, or related conditions and confirmed or ...
Biologics not associated with worse COVID-19 outcomes in RA, PsA or AS patients
By Mardi Chapman
5 May 2020